4.6 Article

Long non-coding RNA RUNXOR accelerates MDSC-mediated immunosuppression in lung cancer

Journal

BMC CANCER
Volume 18, Issue -, Pages -

Publisher

BIOMED CENTRAL LTD
DOI: 10.1186/s12885-018-4564-6

Keywords

lncRNA RUNXOR; MDSCs; RUNX1; Anti-tumor immunity; Lung cancer

Categories

Funding

  1. Summit of the Six Top Talents Program of Jiangsu Province [2015-WSN-116]
  2. Jiangsu Province's Key Medical Talents Program [ZDRCB2016018]
  3. Specialized Project for Clinical Medicine of Jiangsu Province [BL2014065]
  4. Natural Science Foundation of Jiangsu [BK20150533]
  5. China Postdoctoral Science Foundation [2016 M600382]
  6. Jiangsu Postdoctoral Science Foundation [1601082B]

Ask authors/readers for more resources

Background: RUNX1 overlapping RNA (RUNXOR) is a long non-coding RNA that has been indicated as a key regulator in the development of myeloid cells by targeting runt-related transcription factor 1 (RUNX1). Myeloid-derived suppressor cells (MDSCs) are a heterogeneous population of cells consisting of immature granulocytes and monocytes with immunosuppression. However, the impact of lncRNA RUNXOR on the development of MDSCs remains unknown. Methods: Both the expressions of RUNXOR and RUNX1 in the peripheral blood were measured by qRT-PCR. Human MDSCs used in this study were isolated from tumor tissue of patients with lung cancer by FCM or induced from PBMCs of healthy donors with IL-1 beta + GM-CSF. Specific siRNA was used to knockdown the expression of RUNXOR in MDSCs. Results: In this study, we found that the lncRNA RUNXOR was upregulated in the peripheral blood of lung cancer patients. In addition, as a target gene of RUNXOR, the expression of RUNX1 was downregulated in lung cancer patients. Finally, the expression of RUNXOR was higher in MDSCs isolated from the tumor tissues of lung cancer patients compared with cells from adjacent tissue. In addition, RUNXOR knockdown decreased Arg1 expression in MDSCs. Conclusions: Based on our findings, it is illustrated that RUNXOR is significantly associated with the immunosuppression induced by MDSCs in lung cancer patients and may be a target of anti-tumor therapy.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available